Clinical problems of tuberculostatic therapy and acute virus hepatitis.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000917:Antibody Formation; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D005260:Female; D006506:Hepatitis A / Q000139:chemically induced* / Q000276:immunology; D006511:Hepatitis B Antigens / Q000302:isolation & purification; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced; D007565:Jaundice / Q000139:chemically induced; D007931:Leucyl Aminopeptidase / Q000097:blood; D008099:Liver / Q000201:enzymology; D013307:Streptomycin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy
D000995:Antitubercular Agents; D006511:Hepatitis B Antigens; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D007931:Leucyl Aminopeptidase; D001663:Bilirubin; D013307:Streptomycin